PM360

SEPTEMBER 21, 2023

A generic here will improve access in OAB to a product with less side effects, which is especially important in the elderly population, Casberg noted. This increases to 15 Part D drugs in 2026, as well as 15 Part B and D drugs in 2028, and a full 20 Part B and D drugs in 2029.

Management 105

Management Manufacturing Sales Competition 105

European Pharmaceutical Review

JUNE 16, 2023

According to Maximize Market Research , new technologies are expected to boost the clinical trials market between 2022 to 2029, especially as the industry and patients are shifting towards digitalisation approaches and personalised medicines.

Safety 111

Safety Electronics Recruitment Patients 111

European Pharmaceutical Review

AUGUST 30, 2022

Nasal delivery is non-invasive and provides a more targeted delivery than the systemic injectable approach, potentially offering a quicker response and reduced side effects. million by 2029, up from $122.287 million in 2021. These innovations can go a long way towards making nasal a viable route for vaccine development.

Management 119

Management Manufacturing Marketing Side effects 119